Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15/19) - Articles - Oncology · Hematology

Lung, Respiratory and Thoracic Cancer

Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial

Lung Cancer

Isla D, Zugazagoitia J, Arriola E, García-Campelo R, Martí Blanco C, Diz-Taín MP, López-Brea M, Moreno-Vega AL, León-Mateos L, Oramás J, Gutiérrez-Calderón V, Majem M, Sánchez-Hernández A, Aguado C, Alvarez-Cabellos R, Massutí B, Moreno A, Fírvida-Pérez JL, Valdivia J, González-Cordero M, Zafra-Poves M, Dómine M, Garcia-Navalon FJ, Villanueva N, Provencio M, Juan-Vidal O, Rivas-Corredor C, Olmedo García ME, Palmero R, López-Castro R, Carcereny E, Lechuga JL, Domínguez M, Callejo Á, Paz-Ares L

doi: 10.1016/j.lungcan.2025.108763

Lung, Respiratory and Thoracic Cancer

Chemotherapy plus immunotherapy as first line combination in older patients with extensive stage small cell lung cancer: A systematic review and meta-analysis

Semin Oncol

Bertaglia V, Petrelli F, Dottorini L, Carnio S, Morelli AM, Nepote A, Maccioni A, Scartozzi M, Solinas C, Novello S

doi: 10.1053/j.seminoncol.2024.11.001

Lung, Respiratory and Thoracic Cancer

First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial

Lung Cancer

Lee KH, Lee JS, Sugawara S, Kang JH, Kim HR, Inui N, Hida T, Yoshida T, Tanaka H, Yang CT, Inoue T, Nishio M, Ohe Y, Tamura T, Yamamoto N, Yu CJ, Akamatsu H, Takahashi S, Nakagawa K

doi: 10.1016/j.lungcan.2025.108109

Lung, Respiratory and Thoracic Cancer

Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States

Adv Ther

Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S

doi: 10.1007/s12325-025-03408-z

Lung, Respiratory and Thoracic Cancer

Delayed central nervous system progression with atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer (LU23-15)

Lung Cancer

Lee K, Kim TH, Yong Lee S, Lee YG, Choi J, Choi JH, Yoon Choi J, Lim AR, Sun Kim J, Won Lee J, Ji Choi Y, Hyun Park J, Namgung Y, Kyung Ahn H, Joo Kang E

doi: 10.1016/j.lungcan.2025.108455

Lung, Respiratory and Thoracic Cancer

Efficacy and safety of consolidative thoracic radiotherapy for Extensive-Stage Small-Cell lung cancer in the era of immunotherapy: A Real-World study

Lung Cancer

Zhang C, Wang W, Bi N, Wang J, Liu W, Zhang T, Wang X, Xiao Z, Lv J, Feng Q, Deng L, Zhou Z

doi: 10.1016/j.lungcan.2025.108758

Lung, Respiratory and Thoracic Cancer

Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial

J Clin Oncol

Felip E, Altorki N, Zhou C, Vallières E, Csoszi T, Vynnychenko IO, Goloborodko O, Rittmeyer A, Reck M, Martinez-Marti A, Kenmotsu H, Chen YM, Chella A, Sugawara S, Fu C, Ballinger M, Deng Y, Srivastava MK, Bennett E, Gitlitz BJ, Wakelee HA, IMpower010 Study Investigators

doi: 10.1200/JCO-24-01681

Lung, Respiratory and Thoracic Cancer

Lurbinectedin for extensive stage - small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes

Lung Cancer

Krayim B, Shalata W, Bar J, Moskovitz M, Rotem O, Urban D, Sorotsky HG, Kian W, Hanovich E, Marie R, Mann S, Gillis R, Basel A, Kornev G, Asna N, Peled N, Roisman LC

doi: 10.1016/j.lungcan.2025.108598

Lung, Respiratory and Thoracic Cancer

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial

Lancet Oncol

Zhou C, Wang Z, Sun M, Cao L, Ma Z, Wu R, Yu Y, Yao W, Sun S, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Hu C, Liu J, Liu Y, Wang M, Li X, Sun P, Shu Y, Zhou J, Li J, Gu K, Wang C, Zhao H, Zhang Y, Liu C, Yang H, Zhang X, Ma R, Li L, Liang L, Li M, Wang J, Wang Q, Wang B, Dai H, Shi Q, Yang J

doi: 10.1016/S1470-2045(25)00198-6

Related content

Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial

Chemotherapy plus immunotherapy as first line combination in older patients with extensive stage small cell lung cancer: A systematic review and meta-analysis

First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial

Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States

Delayed central nervous system progression with atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer (LU23-15)

Efficacy and safety of consolidative thoracic radiotherapy for Extensive-Stage Small-Cell lung cancer in the era of immunotherapy: A Real-World study

Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial

Lurbinectedin for extensive stage - small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial